Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3716
Gene Symbol: JAK1
JAK1
0.490 CausalMutation disease CGI
Entrez Id: 3716
Gene Symbol: JAK1
JAK1
0.490 GeneticVariation disease BEFREE JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor. 16239216 2005
Entrez Id: 3716
Gene Symbol: JAK1
JAK1
0.490 GeneticVariation disease CLINVAR JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor. 16239216 2005
Entrez Id: 3716
Gene Symbol: JAK1
JAK1
0.490 Biomarker disease BEFREE RESPONSE is an open-label phase 3 study evaluating the Janus kinase 1/Janus kinase 2 inhibitor ruxolitinib versus best available therapy for efficacy/safety in hydroxyurea-resistant or intolerant patients with polycythemia vera. 27102499 2016
Entrez Id: 3716
Gene Symbol: JAK1
JAK1
0.490 Biomarker disease BEFREE The phase 3 RESPONSE trial evaluated the JAK1/JAK2 inhibitor ruxolitinib (n=110) versus best available therapy (BAT; n=112) in patients with PV who were hydroxyurea-resistant/intolerant. 28193568 2017
Entrez Id: 3716
Gene Symbol: JAK1
JAK1
0.490 GeneticVariation disease BEFREE The discovery of a JAK2 point mutation (JAK2 V617F) as the main cause of polycythemia vera lead to the development and FDA approval of a JAK1/2 inhibitor, ruxolitinib, in 2011. 28277287 2017
Entrez Id: 3716
Gene Symbol: JAK1
JAK1
0.490 Biomarker disease BEFREE Since its approval in 2011, the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib has evolved to become the centerpiece of therapy for myelofibrosis (MF), and its use in patients with hydroxyurea resistant or intolerant polycythemia vera (PV) is steadily increasing. 28500170 2017
Entrez Id: 3716
Gene Symbol: JAK1
JAK1
0.490 Biomarker disease BEFREE MAJIC (ISRCTN61925716) is a randomized phase 2 trial of ruxolitinib (JAK1/2 inhibitor) vs best available therapy (BAT) in ET and polycythemia vera patients resistant or intolerant to HC. 29074595 2017
Entrez Id: 3716
Gene Symbol: JAK1
JAK1
0.490 Biomarker disease BEFREE Expert opinion: The JAK1/JAK2 inhibitor ruxolitinib has clearly enriched the therapeutic armamentarium of MPN and is now licenced for more than five years in MF and over three years as second line in PV. 29134817 2017
Entrez Id: 3716
Gene Symbol: JAK1
JAK1
0.490 AlteredExpression disease BEFREE We found that JAK1/2 or JAK2 inhibition prevented the IL-6 activation of STAT3 and AKT pathways in polycythemia vera and HEL cells. 30571852 2019
Entrez Id: 3716
Gene Symbol: JAK1
JAK1
0.490 Biomarker disease BEFREE Ruxolitinib is a JAK1/2 inhibitor approved for the treatment of myelofibrosis (MF) and polycythemia vera (PV). 31711337 2020